This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. IBIO, TAOX, MTNB, AEON, OBSV, NRBO, AEZS, GRAY, CPHI, and OGENShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include iBio (IBIO), Synaptogenix (TAOX), Matinas Biopharma (MTNB), AEON Biopharma (AEON), ObsEva (OBSV), NeuroBo Pharmaceuticals (NRBO), Aeterna Zentaris (AEZS), Graybug Vision (GRAY), China Pharma (CPHI), and Oragenics (OGEN). Novus Therapeutics vs. Its Competitors iBio Synaptogenix Matinas Biopharma AEON Biopharma ObsEva NeuroBo Pharmaceuticals Aeterna Zentaris Graybug Vision China Pharma Oragenics Novus Therapeutics (NASDAQ:NVUS) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Do analysts recommend NVUS or IBIO? iBio has a consensus price target of $5.00, suggesting a potential upside of 532.11%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, NVUS or IBIO? Novus Therapeutics has higher earnings, but lower revenue than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovus TherapeuticsN/AN/A-$16.01M-$21.58-0.12iBio$375K41.46-$24.91MN/AN/A Do institutionals and insiders hold more shares of NVUS or IBIO? 7.9% of iBio shares are owned by institutional investors. 2.2% of Novus Therapeutics shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is NVUS or IBIO more profitable? iBio's return on equity of -73.15% beat Novus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Novus TherapeuticsN/A -133.49% -30.52% iBio N/A -73.15%-45.51% Does the media refer more to NVUS or IBIO? In the previous week, iBio had 4 more articles in the media than Novus Therapeutics. MarketBeat recorded 4 mentions for iBio and 0 mentions for Novus Therapeutics. iBio's average media sentiment score of 0.50 beat Novus Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the news media. Company Overall Sentiment Novus Therapeutics Neutral iBio Neutral Which has more risk & volatility, NVUS or IBIO? Novus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, iBio has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. SummaryiBio beats Novus Therapeutics on 8 of the 12 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.73M$832.60M$5.76B$9.58BDividend YieldN/A4.84%4.41%4.10%P/E Ratio-0.121.1731.1026.05Price / SalesN/A26.34433.22103.03Price / CashN/A19.5637.7358.48Price / Book0.206.659.536.61Net Income-$16.01M-$4.94M$3.26B$265.56M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$2.60+1.6%N/A-13.2%$3.73MN/A-0.127High Trading VolumeIBIOiBio1.9179 of 5 stars$0.73-1.3%$5.00+582.2%-60.3%$12.27M$375K0.00100News CoverageGap DownTAOXSynaptogenixN/A$6.96-16.5%N/AN/A$11.59MN/A-0.354Earnings ReportGap UpMTNBMatinas Biopharma0.7235 of 5 stars$1.70-0.6%N/AN/A$8.65MN/A-0.3530AEONAEON Biopharma2.9126 of 5 stars$0.73-3.2%$360.00+49,147.6%-98.9%$8.26MN/A4.065Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap DownNRBONeuroBo PharmaceuticalsN/A$0.65+1.7%N/A-82.5%$5.61MN/A0.0010High Trading VolumeAEZSAeterna ZentarisN/A$2.89+1.4%N/A-55.3%$5.18M$2.37M-0.1920GRAYGraybug VisionN/A$2.94+1.1%N/A-33.3%$4.62MN/A-1.7027Gap UpHigh Trading VolumeCPHIChina PharmaN/A$1.41-4.1%N/A-93.2%$4.60M$4.30M0.00250Gap UpOGENOragenics0.2279 of 5 stars$1.06-3.6%N/A-95.9%$4.54MN/A-0.155Short Interest ↓ Related Companies and Tools Related Companies IBIO Alternatives TAOX Alternatives MTNB Alternatives AEON Alternatives OBSV Alternatives NRBO Alternatives AEZS Alternatives GRAY Alternatives CPHI Alternatives OGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access